E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary (PMF) or secondary (SMF) myelofibrosis. |
|
E.1.1.1 | Medical condition in easily understood language |
Primary (PMF) or secondary (SMF) myelofibrosis. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10077161 |
E.1.2 | Term | Primary myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074691 |
E.1.2 | Term | Post polycythaemia vera myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074690 |
E.1.2 | Term | Post essential thrombocythemia myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects of 1000 mg BID GB2064 in participants with PMF or SMF. |
|
E.2.2 | Secondary objectives of the trial |
- To assess the pharmacokinetics (PK) in blood of GB2064 in participants with PMF or SMF; - To assess the effect of GB2064 on clinical parameters of disease activity in participants with PMF or SMF; - To assess the effect of GB2064 on MFrelated symptoms and quality of life (QoL); - To assess the effect of GB2064 on the bone marrow. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The main inclusion criteria include a diagnosis of PMF or SMF, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and clinical laboratory parameters within appropriate limits for participants with MF. |
|
E.4 | Principal exclusion criteria |
Participants are excluded if they are taking or have taken a JAK inhibitor (ruxolitinib or fedratinib) within two weeks of enrolment or chronic (> 14 days) treatment with corticosteroids at a dose up to 60 mg prednisone per day (or its glucocorticoid equivalent) for a maximum of 4 weeks once enrolled in the study, during which the dose should be tapered to ≤10mg per day, if needed for maintenance, before potentially being discontinued at the Investigators discretion. The dosage of corticosteroids for JAK inhibitor naïve participants should not exceed 10 mg per day should it be necessary while the participant is on the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Adverse events (AE), serious adverse events (SAE), clinical laboratory assessments, vital signs, ECG, physical examination, body weight. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At screening and during the study. |
|
E.5.2 | Secondary end point(s) |
1. Pre-dose and post-dose plasma levels of GB2064 2. Clinical parameters including, but not limited to changes in anaemia, platelets and transfusion dependence, splenic volume. 3. Clinical Benefit Rate (CBR) and Overall Survival (OS) (Tefferi et al. 2013) 4. Patient-reported assessments of symptoms and quality of life, as measured by MPN10 and EQ-5D-5L 5. Histopathological examination of bone marrow biopsy tissue including the extent of fibrosis |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Each month during the study. 2. At screening and during the study. 3. During the study. 4. On Day 1 and Month, 3, 6 and 9. 5. On Day 1 and Month, 3, 6 and 9. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
United States |
Germany |
Italy |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |